U.S. Stocks Movement: Omeros Pharmaceuticals plunges on October 16 after narsoplimab rejected again by the EU + approval stalled

Omeros Pharmaceuticals October 16: Major Decline Analysis

Keywords: Narsoplimab Rejected Again by EU, Approval Obstructed

On October 16, the European Medicines Agency's Committee for Medicinal Products for Human Use, after reconsideration, maintained a negative opinion on Omeros' application for EU approval of narsoplimab for the treatment of transplant-associated thrombotic microangiopathy (TA-TMA), confirming the negative stance from June 2026. The drug has not received an EU marketing recommendation, and its commercialization process in Europe is hindered.

(Disclaimer: This content is generated by AI technology based on publicly available information and is for reference only. It does not constitute investment advice.)